NO20054912L - Behandling av aspergillus infeksjoner med tymosin alfa 1 - Google Patents

Behandling av aspergillus infeksjoner med tymosin alfa 1

Info

Publication number
NO20054912L
NO20054912L NO20054912A NO20054912A NO20054912L NO 20054912 L NO20054912 L NO 20054912L NO 20054912 A NO20054912 A NO 20054912A NO 20054912 A NO20054912 A NO 20054912A NO 20054912 L NO20054912 L NO 20054912L
Authority
NO
Norway
Prior art keywords
thymosin alpha
treatment
aspergillus
aspergillus infections
immuno
Prior art date
Application number
NO20054912A
Other languages
English (en)
Other versions
NO20054912D0 (no
NO329997B1 (no
Inventor
Guido Rasi
Enrico Garaci
Francesco Bistoni
Luigina Romani
Paolo Di Firancesco
Original Assignee
Sciclone Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sciclone Pharmaceuticals Inc filed Critical Sciclone Pharmaceuticals Inc
Publication of NO20054912D0 publication Critical patent/NO20054912D0/no
Publication of NO20054912L publication Critical patent/NO20054912L/no
Publication of NO329997B1 publication Critical patent/NO329997B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2292—Thymosin; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO20054912A 2003-03-28 2005-10-24 Anvendelse av TA1 for fremstilling av et farmasoytisk preparat for behandling eller forebygging av en Aspergillus-infeksjon i et pattedyr. NO329997B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45791103P 2003-03-28 2003-03-28
PCT/US2004/009550 WO2004087067A2 (en) 2003-03-28 2004-03-29 Treatment of aspergillus infections with thymosin alpha 1

Publications (3)

Publication Number Publication Date
NO20054912D0 NO20054912D0 (no) 2005-10-24
NO20054912L true NO20054912L (no) 2005-12-20
NO329997B1 NO329997B1 (no) 2011-02-07

Family

ID=42828702

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20054912A NO329997B1 (no) 2003-03-28 2005-10-24 Anvendelse av TA1 for fremstilling av et farmasoytisk preparat for behandling eller forebygging av en Aspergillus-infeksjon i et pattedyr.

Country Status (17)

Country Link
US (2) US8207294B2 (no)
EP (1) EP1613340B1 (no)
JP (1) JP4629033B2 (no)
KR (1) KR101089145B1 (no)
AT (1) ATE467422T1 (no)
AU (1) AU2004226403B2 (no)
BR (1) BRPI0408892A (no)
CA (1) CA2520400C (no)
DK (1) DK1613340T3 (no)
EA (1) EA008037B1 (no)
IL (1) IL171118A (no)
MX (1) MXPA05010391A (no)
NO (1) NO329997B1 (no)
NZ (1) NZ542900A (no)
PL (1) PL1613340T3 (no)
UA (1) UA80870C2 (no)
WO (1) WO2004087067A2 (no)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2520400C (en) 2003-03-28 2013-02-19 Sciclone Pharmaceuticals, Inc. Treatment of aspergillus infections with thymosin alpha 1
WO2006062917A2 (en) * 2004-12-06 2006-06-15 Sciclone Pharmaceuticals, Inc. Alpha thymosin peptides as cancer vaccine adjuvants
ES2553267T3 (es) * 2006-05-19 2015-12-07 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Timosina alfa 1 para uso en el tratamiento de la enfermedad de injerto contra huésped
ITRM20060583A1 (it) * 2006-10-27 2008-04-28 Francesco Bistoni Uso della timosina alfa 1 per la preparazione di un medicamento per la prevenzione e la cura delle allergie
CN103458681A (zh) * 2011-02-09 2013-12-18 赛生制药有限公司 用于预防感染、降低感染的严重性、及治疗感染的胸腺素α肽
AU2016217473B2 (en) * 2015-02-09 2021-07-29 Sci Clone Pharmaceuticals International (Sg) Pte. Ltd. Thymosin alpha 1 for use in treatment of cystic fibrosis
ITUB20153714A1 (it) * 2015-09-18 2017-03-18 Luigina Romani Timosina alfa 1 per l?uso nel trattamento della fibrosi cistica.

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4002740A (en) 1975-08-21 1977-01-11 Gideon Goldstein Tridecapeptide compositions and methods
US4079127A (en) 1976-10-28 1978-03-14 Board Of Regents Of The University Of Texas Thymosin alpha 1
US4116951A (en) 1977-04-22 1978-09-26 Hoffmann-La Roche Inc. [Asn2 ]-thymosin α1 and analogs thereof
DE2919592A1 (de) 1979-05-15 1981-01-15 Max Planck Gesellschaft Verfahren zur herstellung von thymosin- alpha 1 und derivaten davon
US4612365A (en) 1980-03-25 1986-09-16 Max-Planck-Gesellschaft Zur Foederung Der Wissenschaften Medicaments containing alpha 1-thymosin and having an immuno regulatory action and alpha 1-thymosin fragments
US4374197A (en) 1980-10-30 1983-02-15 Hoffmann-La Rocche Inc. Process for thymosin α1
TW224053B (no) * 1991-09-13 1994-05-21 Paul B Chretien
CN1058500C (zh) 1993-02-03 2000-11-15 施塞克龙药品公司 胸腺素α－1衍生物
CN1072961C (zh) 1993-03-05 2001-10-17 施塞克龙药品公司 治疗对干扰素治疗无反应者的丙型肝炎的方法
TW252045B (no) * 1993-10-07 1995-07-21 Allan L Goldstein
RU2107692C1 (ru) * 1995-06-07 1998-03-27 Дейгин Владислав Исакович Пептид и способ его получения
US5888980A (en) 1994-06-30 1999-03-30 Bio-Logic Research And Development Corporation Compositions for enhancing immune function
US5632983A (en) 1994-11-17 1997-05-27 University Of South Florida Method for treating secondary immunodeficiency
WO1998035696A1 (en) * 1997-02-18 1998-08-20 Sciclone Pharmaceuticals, Inc. Use of thymosin alpha 1 for the manufacture of a medicament for promoting stem cell development
UA80957C2 (en) * 2001-11-01 2007-11-26 Sciclone Pharmaceuticals Inc Method of administering a thymosin alpha 1 peptide
CA2520400C (en) 2003-03-28 2013-02-19 Sciclone Pharmaceuticals, Inc. Treatment of aspergillus infections with thymosin alpha 1

Also Published As

Publication number Publication date
CA2520400C (en) 2013-02-19
KR20050114264A (ko) 2005-12-05
AU2004226403A1 (en) 2004-10-14
EP1613340A2 (en) 2006-01-11
UA80870C2 (en) 2007-11-12
US8207294B2 (en) 2012-06-26
AU2004226403B2 (en) 2008-12-04
PL1613340T3 (pl) 2010-10-29
WO2004087067A2 (en) 2004-10-14
US8389680B2 (en) 2013-03-05
JP2006521406A (ja) 2006-09-21
US20070129292A1 (en) 2007-06-07
CA2520400A1 (en) 2004-10-14
EP1613340A4 (en) 2009-07-01
MXPA05010391A (es) 2005-11-04
WO2004087067A3 (en) 2004-12-29
EP1613340B1 (en) 2010-05-12
KR101089145B1 (ko) 2011-12-02
BRPI0408892A (pt) 2006-04-11
NZ542900A (en) 2007-06-29
US20120295840A1 (en) 2012-11-22
ATE467422T1 (de) 2010-05-15
DK1613340T3 (da) 2010-08-30
IL171118A (en) 2011-10-31
EA008037B1 (ru) 2007-02-27
JP4629033B2 (ja) 2011-02-09
NO20054912D0 (no) 2005-10-24
NO329997B1 (no) 2011-02-07
EA200501414A1 (ru) 2006-04-28

Similar Documents

Publication Publication Date Title
NO20054912D0 (no) Behandling av aspergillus infeksjoner med tymosin alfa 1
DK1599575T3 (da) Fremgangsmåder til anvendelse af adipøst vævs-afledte celler i behandlingen af kardiovaskulære tilstande
ATE319312T1 (de) Suppressorzellen zur prävention und behandlung von immunantworten bei transplantationen
DE602005026294D1 (de) Verwendung einer kombination von cyclosporin und pegylierten interferonen zur behandlung von hepatitis c (hcv)
DE60045034D1 (de) Überstände von mesenchymstammzellen zur vorbeugung und behandlung von immunantworten in transplantationen
ATE539701T1 (de) Zusammengesetzte schlinge zur behandlung von inkontinenz
DK1885382T3 (da) Fremgangsmåder til anvendelse af adipøst vævs-afledte celler i behandlingen af cardiovaskulære tilstande
DE60328476D1 (de) Medizinisches ballonsystem zur behandlung von adipositas
ATE427116T1 (de) Behandlung von bakteriellen infektionen
DE602004031134D1 (de) Pharmazeutische zusammensetzungen und verfahren zur verwendung von levodopa und carbidopa
EA201100413A1 (ru) Способ лечения бактериальной инфекции
DK1778833T3 (da) Fremgangsmåder til anvendelse af regenerative celler til at fremme sårheling
DE69829202D1 (de) Verwendung von mirtazapine zur herstellung eines medikaments zur behandlung von schlafapnoen
WO2006022612A3 (en) Methods of using regenerative cells in the treatment of stroke and related diseases and disorders
DK1663233T3 (da) Anvendelse af tigecyclin, alene eller i kombination med rifampin til behandling af osteomyelitis og/eller septisk arthritis
DE602004014189D1 (de) Zusammensetzungen und verfahren zur behandlung von hepatitis-c-virus (hcv) infektion
DE50210987D1 (de) Verbindungen zur beseitigung und/oder linderung der anhedonie
CY1110218T1 (el) Αγωγη των λοιμωξεων απο ασπεργιλλο με θυμοσινη αλφα 1
EA200600989A1 (ru) Применение габоксадола для лечения бессонницы
ATE544453T1 (de) Kombinationstherapien mit l-fmau zur behandlung von hepatitis-b-virus-infektionen
ATE406911T1 (de) Fisch-impfstoff
Macgregor Set a bug to catch a bug.
NO20062138L (no) Anvendelse av ifenprodil i behandling av smerte
TR200000540T2 (tr) Virütik ve mikrobiyal enfeksiyonları ve aşırı zayıflama sendromlarını tedavi etmek için ilaç ulaştırma araçları ve yöntemleri.
WO2002059606A3 (en) Targets and therapeutic agents for the treatmnt of epstein-barr virus infection

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees